Yüklüyor......
An emerging treatment option for glaucoma: Rho kinase inhibitors
Rho kinase (ROCK) inhibitors are a novel potential class of glaucoma therapeutics with multiple compounds currently in Phase II and III US Food and Drug Administration trials in the United States. These selective agents work by relaxing the trabecular meshwork through inhibition of the actin cytoske...
Kaydedildi:
| Asıl Yazarlar: | , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Dove Medical Press
2014
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4025933/ https://ncbi.nlm.nih.gov/pubmed/24872673 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OPTH.S41000 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|